معرفی
Dr. Ali Parlar is an Associate Professor of Medical Pharmacology at Adıyaman University Faculty of Medicine, where he has been serving since 2012. Previously, he held positions at Mustafa Kemal University Faculty of Veterinary Medicine and had a temporary assignment at Düzce University Faculty of Medicine. With a doctorate in Pharmacology and Toxicology from Ankara University completed in 2001, Dr. Parlar has established himself as a prominent researcher in pharmacological mechanisms of natural compounds and inflammation pathways.
Dr. Parlar's research primarily focuses on the pharmacological effects of natural compounds including glabridin (from licorice), thymoquinone (from Nigella sativa), and cannabinoid receptor agonists. His work investigates their mechanisms in conditions such as asthma, pulmonary fibrosis, intestinal ischemia-reperfusion injury, and neuroinflammation. He has published extensively on how these compounds modulate BKCa channels, cytokine production, and oxidative stress in various animal models.
His publication record includes 36 articles in reputable journals and co-authorship of books on Ethnobotany and Ethnopharmacology published by Routledge Taylor Francis in 2023. Dr. Parlar serves as an Assistant Editor for several journals including Advances in Pharmacology Clinical Trials, Virtus Journal, and Boletin Latinoamericano y del Caribe de Plantas Medicinales y Aromaticas, and performs peer review work for multiple pharmacology journals.
- ULAKBİM-CABİM Yayın Teşvik Ödülü (Publication Incentive Award) from TÜBİTAK
- Extensive research on cannabinoid receptor mechanisms in inflammatory conditions
- Investigation of natural compounds for therapeutic applications
- Editorial roles in multiple international pharmacology journals
Dr. Parlar's work bridges traditional pharmacological approaches with emerging research on natural compounds, contributing significantly to understanding inflammation mechanisms and potential therapeutic interventions. His research has practical implications for developing novel treatments for respiratory, cardiovascular, and neurodegenerative conditions.
